Autoimmune chronic spontaneous urticaria: What we know and what we do not know

被引:217
|
作者
Kolkhir, Pavel [1 ,2 ]
Church, Martin K. [2 ]
Weller, Karsten [2 ]
Metz, Martin [2 ]
Schmetzer, Oliver [2 ]
Maurer, Marcus [2 ]
机构
[1] LM Sechenov First Moscow State Med Univ, Dept Dermatol & Venereol, Moscow, Russia
[2] Charite, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany
关键词
Chronic spontaneous urticaria; autoimmunity; IgE-anti-self; IgG-anti-Fc epsilon RI/IgE; causality; Hill's criteria of causality; CHRONIC IDIOPATHIC URTICARIA; SERUM SKIN-TEST; FC-EPSILON-RI; ANTI-IGE AUTOANTIBODIES; AUTOLOGOUS SERUM; HISTAMINE-RELEASE; ANTITHYROID ANTIBODIES; CLINICAL-FEATURES; BASOPHIL NUMBERS; IMMUNOGLOBULIN-E;
D O I
10.1016/j.jaci.2016.08.050
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Chronic spontaneous urticaria (CSU) is a mast cell-driven skin disease characterized by the recurrence of transient wheals, angioedema, or both for more than 6 weeks. Autoimmunity is thought to be one of the most frequent causes of CSU. Type I and II autoimmunity (ie, IgE to autoallergens and IgG autoantibodies to IgE or its receptor, respectively) have been implicated in the etiology and pathogenesis of CSU. We analyzed the relevant literature and assessed the existing evidence in support of a role for type I and II autoimmunity inCSUwith the help of Hill's criteria of causality. For each of these criteria (ie, strength of association, consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment, and analogy), we categorized the strength of evidence as "insufficient," "low," "moderate," or "high" and then assigned levels of causality for type I and II autoimmunity in patients with CSU from level 1 (causal relationship) to level 5 (causality not likely). Based on the evidence in support of Hill's criteria, type I autoimmunity in patients with CSU has level 3 causality (causal relationship suggested), and type II autoimmunity has level 2 causality (causal relationship likely). There are still many aspects of the pathologic mechanisms of CSU that need to be resolved, but it is becoming clear that there are at least 2 distinct pathways, type I and type II autoimmunity, that contribute to the pathogenesis of this complex disease.
引用
收藏
页码:1772 / +
页数:11
相关论文
共 50 条
  • [1] Cold urticaria - What we know and what we do not know
    Maltseva, Natalya
    Borzova, Elena
    Fomina, Daria
    Bizjak, Mojca
    Terhorst-Molawi, Dorothea
    Kosnik, Mitja
    Kulthanan, Kanokvalai
    Meshkova, Raisa
    Thomsen, Simon Francis
    Maurer, Marcus
    [J]. ALLERGY, 2021, 76 (04) : 1077 - 1094
  • [2] 35 years of autologous serum skin test in chronic spontaneous urticaria: what we know and what we do not know
    Asero, R.
    Pinter, E.
    Tedeschi, A.
    [J]. EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 55 (01) : 4 - 8
  • [3] Autoimmune pancreatitis - What we know and what do we have to know?
    Qureshi, Ammar
    Ghobrial, Youssef
    De Castro, Joline
    Siami-Namini, Koushan
    Newman, Kam A.
    [J]. AUTOIMMUNITY REVIEWS, 2021, 20 (10)
  • [4] Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know
    Dorothea Terhorst-Molawi
    Lena Fox
    Frank Siebenhaar
    Martin Metz
    Marcus Maurer
    [J]. American Journal of Clinical Dermatology, 2023, 24 : 397 - 404
  • [5] Urticaria Management in North America: What We Know and What We Do Not Know
    Zheng, Jiayue
    Pasquini, Veronica Ferris
    Lima, Hermenio
    [J]. CURRENT TREATMENT OPTIONS IN ALLERGY, 2024, 11 (03) : 150 - 158
  • [6] Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don't Know
    Terhorst-Molawi, Dorothea
    Fox, Lena
    Siebenhaar, Frank
    Metz, Martin
    Maurer, Marcus
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (03) : 397 - 404
  • [7] Chronic prostatitis: what we know, what we do not know, and what we should do!
    Lobel, B
    Rodriguez, A
    [J]. WORLD JOURNAL OF UROLOGY, 2003, 21 (02) : 57 - 63
  • [8] Chronic prostatitis: what we know, what we do not know, and what we should do!
    B. Lobel
    A. Rodriguez
    [J]. World Journal of Urology, 2003, 21 : 57 - 63
  • [9] What we know and what we do not know
    McDonald, JC
    [J]. RADIATION PROTECTION DOSIMETRY, 2005, 113 (02) : 127 - 128
  • [10] Quasicrystals: What do we know? What do we want to know? What can we know?
    Steurer, Walter
    [J]. ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : 1 - 11